Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05470699 · ClinicalTrials.gov registry record · NA

RefleXion PET/CT Imaging Performance in Patients With Prostate Cancer

A NA study of Prostate Carcinoma, sponsored by City of Hope Medical Center.

Active
Registry status
NA
Development phase
34
Enrollment target
1
Study location

NCT05470699 is a NA study of Prostate Carcinoma that is active but no longer recruiting, run by City of Hope Medical Center. The registered enrollment target is 34 participants, below the 1,501-participant average among 59 other Prostate Carcinoma trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05470699, a NA study of Prostate Carcinoma, is active but no longer recruiting, sponsored by City of Hope Medical Center.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
34 participants
Enrollment target
1
Study location

Study Summary

This clinical trial examines RefleXion Medical Radiotherapy System (RMRS) imaging to the standard of care (SOC) \[18F\]-DCFPyL positron emission tomography-computed tomography (PET-CT) imaging in patients with prostate cancer. PET is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of a tracer, \[18F\]-DCFPyL, that binds to prostate specific membrane antigen (PSMA) on tumor cells. These PSMA tumor cells can then be identified on PET imaging. CT utilizes x-rays that traverse body from the outside. CT images provide an exact outline of organs and potential inflammatory tissue where it occurs in patient's body. The RMRS is a imaging-therapy combination system that can plan for and deliver radiation therapy as well perform \[18F\]-DCFPyL PET-CT imaging. Comparing the imaging from the standard of care \[18F\]-DCFPyL-PET-CT with the \[18F\]-DCFPyL imaging from RMRS may help improve the quality of the imaging captured and determine if imaging can be done on the RMRS at the same time as planning for radiation therapy, which would reduce the number of scans needed to plan for radiation for prostate cancer.

Conditions Studied

Prostate Carcinoma

Interventions

  • PROCEDURE Computed Tomography
  • OTHER Fluorine F 18 Piflufolastat
  • DEVICE Positron Emission Tomography

Study Locations (1)

California

  • City of Hope Medical Center - Duarte

Trial Details

FieldValue
Enrollment Target 34 participants
Start Date 2022-08-29
Est. Completion 2026-04-13
Phase NA

Sponsor

City of Hope Medical Center

582 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05470699

The ClinicalTrials.gov registry entry for NCT05470699 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,501-participant average among 59 other Prostate Carcinoma trials with a reported enrollment target (98% lower). The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Prostate Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Computed Tomography is the first listed.

NCT05470699 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT05470699 about?

NCT05470699 is a clinical study titled "RefleXion PET/CT Imaging Performance in Patients With Prostate Cancer". This clinical trial examines RefleXion Medical Radiotherapy System (RMRS) imaging to the standard of care (SOC) \[18F\]-DCFPyL positron emission tomography-computed tomography (PET-CT) imaging in patients with prostate cancer. PET is an established imaging technique that utilizes small amounts of ra...

What is the current status of trial NCT05470699?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 34 participants. The study started on 2022-08-29. Estimated completion is 2026-04-13.

What conditions does trial NCT05470699 study?

This clinical trial studies the following conditions: Prostate Carcinoma.

What interventions are being tested in trial NCT05470699?

The interventions under investigation include: Computed Tomography (PROCEDURE), Fluorine F 18 Piflufolastat (OTHER), Positron Emission Tomography (DEVICE).

Who is sponsoring clinical trial NCT05470699?

This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05470699 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Prostate Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Prostate Carcinoma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.